SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will webcast its investor update, in conjunction with the American College of Rheumatology Meeting (ACR), on October 27, 2008 from 2:00-3:00pm Pacific Time. Members of Rigel's senior management team will provide an update on the company's lead product candidate, R788, a novel, oral Syk kinase inhibitor. R788 is currently being evaluated in two Phase 2b clinical trials in patients with rheumatoid arthritis, as well as Phase 2 clinical trials in immune thrombocytopenic purpura and B-cell lymphomas.
The event will be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary. The webcast will be archived and available for replay on the Company's website.
In addition, Rigel will be participating in both a plenary session and
a poster session during ACR in San Francisco, California from October
ACR Presentation Details
Plenary session: Monday, Oct 27, 12:15-12:30 PM
Session: Discovery 2008: Pathogenesis and Treatment of Inflammatory
Title: 1189 - Treatment of Rheumatoid Arthritis (RA) with a Syk Kinase
Inhibitor: A 12-week randomized placebo controlled study
Location: Hall C
Poster session: Tuesday, Oct 28, 9:00-11:00 AM
Session: Biology and Pathology of Bone and Cartilage
Title: 1293 - R406, a Small Molecule Syk inhibitor, Suppresses Osteoclast
Differentiation of Murine Bone Marrow Progenitor Cells
Location: Hall A, Poster Board: 15
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and
develops novel, small-molecule drugs for the treatment of
inflammatory/autoimmune diseases and cancer, as well as viral and metabolic
diseases. Our pioneering research focuses on intracellular signaling
pathways and related targets that are critical to disease mechanisms.
Rigel's productivity has resulted in strategic collaborations with large
pharmaceutical partners to develop and market our product candidates. Rigel
has product development programs in inflammatory/autoimmune diseases such
as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Contact: Raul Rodriguez
Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
|SOURCE Rigel Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved